Atropine sulfate
(Synonyms: 硫酸阿托品; 硫酸阿妥品; 硫酸阿托平; 硫酸阿脱品; Tropine tropate sulfate; DL-Hyoscyamine sulfate; Sulfatropinol) 目录号 : GC35428
A non-
Cas No.:55-48-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Atropine is a naturally occurring tropane alkaloid extracted from plants of the family Solanaceae including deadly nightshade (A. belladonna). It is a non-
1.Caulfield, M.P., and Birdsall, N.J.M.International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptorsPharmacol. Rev.50(2)279-290(1998) 2.Broadley, K.J., and Kelly, D.R.Muscarinic receptor agonists and antagonistsMolecules6(3)142-193(2001) 3.Grynkiewicz, G., and Gadzikowska, M.Tropane alkaloids as medicinally useful natural products and their synthetic derivatives as new drugsPharmacol. Rep.60(4)439-463(2008)
| Cas No. | 55-48-1 | SDF | |
| 别名 | 硫酸阿托品; 硫酸阿妥品; 硫酸阿托平; 硫酸阿脱品; Tropine tropate sulfate; DL-Hyoscyamine sulfate; Sulfatropinol | ||
| Canonical SMILES | O=C(O[C@@H]1C[C@@H](N2C)CC[C@@H]2C1)C(CO)C3=CC=CC=C3.[0.5H2SO4] | ||
| 分子式 | C17H23NO3 . 1/2 H2O4S | 分子量 | 338.41 |
| 溶解度 | DMSO : 18mg/mL | 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.955 mL | 14.775 mL | 29.55 mL |
| 5 mM | 0.591 mL | 2.955 mL | 5.91 mL |
| 10 mM | 0.2955 mL | 1.4775 mL | 2.955 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Atropine sulfate--a current review of a useful agent for controlling salivation during dental procedures
Gen Dent 1999 Jan-Feb;47(1):56-60; quiz 62-3.PMID:10321153doi
After reading this article, the reader should be able to describe techniques for the control of saliva during dental procedures; discuss the problems associated with saliva contamination of an operative field; explain the clinical benefits, dosing guidelines, and contraindications for using Atropine sulfate to temporarily reduce saliva flow during dental procedures.
Hospital-prepared low-dose atropine eye drops for myopia progression control using Atropine sulfate injection diluted in normal saline and lubricants
BMC Res Notes 2022 Nov 5;15(1):342.PMID:36335388DOI:10.1186/s13104-022-06240-8.
Objective: As low-dose atropine eye-drops for myopia progression control prepared in-house by diluting the commercial 0.1% atropine eye-drop with sterile water or normal saline has been a common practice whereas atropine injection is readily available and could be a more feasible alternative, this study aimed to assess the properties of the in-house low-dose atropine eye-drops prepared by diluting the atropine injection in two solvents and tested in two temperature conditions. Results: The 0.01% atropine eye-drops contains no bacteria, fungi, or particulate matter. The levels of Atropine sulfate on all samples were comparable to the freshly prepared samples at the 12th week, regardless of the solvents used or storage conditions. The low-dose atropine eye-drops prepared from readily available Atropine sulfate injection at healthcare facilities could be an alternative to commercial products.
Inhaled Atropine sulfate in acute asthma
Respiration 1981;42(4):263-72.PMID:7330469DOI:10.1159/000194441.
We administered inhaled Atropine sulfate to acute asthmatics already receiving therapeutic doses of adrenergic agonists, theophylline, and corticosteroids. Following atropine, hyperinflation diminished whereas vital capacity and expiratory flow rates breathing air and helium-oxygen increased (p less than 0.025 - p less than 0.005). Initial density dependence correlated inversely with changes in density dependence after atropine (r = -0.69, p less than 0.001). We conclude that: (1) inhaled Atropine sulfate was effective therapy for acutely ill asthmatics already being treated with multiple antiasthmatic agents; (2) atropine caused large and peripheral airways bronchodilatation, and (3) the predominant site of bronchodilatation after atropine was related to the site of flow limitation before atropine.
Pharmacokinetics and efficacy of Atropine sulfate/obidoxime chloride co-formulation against VX in a guinea pig model
Regul Toxicol Pharmacol 2021 Feb;119:104823.PMID:33212192DOI:10.1016/j.yrtph.2020.104823.
Nerve agent exposure is generally treated by an antidote formulation composed of a muscarinic antagonist, Atropine sulfate (ATR), and a reactivator of acetylcholinesterase (AChE) such as pralidoxime, obidoxime (OBI), methoxime, trimedoxime or HI-6 and an anticonvulsant. Organophosphates (OPs) irreversibly inhibit AChE, the enzyme responsible for termination of acetylcholine signal transduction. Inhibition of AChE leads to overstimulation of the central and peripheral nervous system with convulsive seizures, respiratory distress and death as result. The present study evaluated the efficacy and pharmacokinetics (PK) of ATR/OBI following exposure to two different VX dose levels. The PK of ATR and OBI administered either as a single drug, combined treatment but separately injected, or administered as the ATR/OBI co-formulation, was determined in plasma of naïve guinea pigs and found to be similar for all formulations. Following subcutaneous VX exposure, ATR/OBI-treated animals showed significant improvement in survival rate and progression of clinical signs compared to untreated animals. Moreover, AChE activity after VX exposure in both blood and brain tissue was significantly higher in ATR/OBI-treated animals compared to vehicle-treated control. In conclusion, ATR/OBI has been proven to be efficacious against exposure to VX and there were no PK interactions between ATR and OBI when administered as a co-formulation.
Efficacy of Atropine sulfate/obidoxime chloride co-formulation against sarin exposure in guinea pigs
Chem Biol Interact 2018 Dec 25;296:34-42.PMID:30217478DOI:10.1016/j.cbi.2018.09.004.
The efficacy and pharmacokinetics of the aqueous co-formulation contents of the Trobigard™ (Atropine sulfate, obidoxime chloride) auto-injector were evaluated in a sarin exposed guinea pig model. Two subcutaneous (sc) sarin challenge doses were evaluated in guinea pigs instrumented with brain and heart electrodes for electroencephalogram (EEG) and electrocardiogram (ECG). Sarin challenge doses were chosen to reflect exposure subclasses with sublethal (moderate to severe clinical signs) and lethal consequences. The level of protection of intramuscular human equivalent doses of the co-formulation was defined by (1) the mitigation of signs and symptoms at a sublethal level and (2) the increase of survival time at the supralethal sarin dose levels. Pharmacokinetics of both Atropine sulfate and obidoxime were proportional at 1 and 3 human equivalent doses, and only a small increase in heart rate was observed briefly as a side effect. At both sarin challenge doses, 54 μg/kg and 84 μg/kg, the co-formulation treatment was effective against sarin-induced effects. Survival rates were improved at both sarin challenge levels, whereas clinical signs and changes in EEG activity could not in all cases be effectively mitigated, in particular at the supralethal sarin challenge dose level. Reactivation of sarin inhibited cholinesterase was observed in blood, and higher brain cholinesterase activity levels were associated with a better clinical condition of the co-formulation treated animals. Although the results cannot be directly extrapolated to the human situation, pharmacokinetics and the effects over time related to plasma levels of therapeutics in a freely moving guinea pig could aid translational models and possibly improve prediction of efficacy in humans.